BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) has received an average rating of “Moderate Buy” from the twenty-two research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nineteen have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $104.42.
A number of brokerages have issued reports on BBIO. Jefferies Financial Group reiterated a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, October 5th. Barclays cut their target price on BridgeBio Pharma from $157.00 to $156.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 7th. Canaccord Genuity Group raised their price target on BridgeBio Pharma from $106.00 to $108.00 and gave the company a “buy” rating in a report on Monday, November 2nd. Bank of America lifted their price target on BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research report on Tuesday, October 6th.
View Our Latest Stock Report on BBIO
Insider Activity at BridgeBio Pharma
In other news, CEO Neil Kumar sold 10,000 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $69.08, for a total transaction of $690,800.00. Following the transaction, the chief executive officer directly owned 495,686 shares of the company’s stock, valued at $34,241,988.88. This represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction on Friday, October 30th. The shares were sold at an average price of $72.85, for a total value of $145,700.00. Following the sale, the chief accounting officer directly owned 120,687 shares in the company, valued at $8,792,047.95. This trade represents a 1.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 22,000 shares of company stock worth $1,676,800 over the last ninety days. 14.23% of the stock is currently owned by insiders.
Institutional Trading of BridgeBio Pharma
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bellevue Group AG lifted its position in BridgeBio Pharma by 0.6% during the third quarter. Bellevue Group AG now owns 1,196,669 shares of the company’s stock valued at $78,741,000 after purchasing an additional 7,163 shares in the last quarter. Integral Health Asset Management LLC grew its holdings in BridgeBio Pharma by 9.1% during the third quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock valued at $19,740,000 after purchasing an additional 25,000 shares during the period. Jump Financial LLC purchased a new stake in BridgeBio Pharma in the third quarter worth about $304,000. Marshall Wace LLP increased its position in BridgeBio Pharma by 43.0% in the third quarter. Marshall Wace LLP now owns 393,946 shares of the company’s stock worth $25,922,000 after buying an additional 118,430 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in BridgeBio Pharma in the third quarter worth about $8,689,000. 99.85% of the stock is owned by hedge funds and other institutional investors.
BridgeBio Pharma Trading Down 1.2%
NASDAQ:BBIO opened at $77.36 on Thursday. The firm’s fifty day simple moving average is $70.03 and its 200 day simple moving average is $72.79. BridgeBio Pharma has a twelve month low of $62.50 and a twelve month high of $93.42.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.12. The firm had revenue of $353.17 million during the quarter, compared to analysts’ expectations of $293.47 million. During the same quarter in the previous year, the business earned ($0.95) EPS. The company’s revenue for the quarter was up 192.6% compared to the same quarter last year. On average, analysts expect that BridgeBio Pharma will post -2.55 EPS for the current year.
About BridgeBio Pharma
BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.
Featured Articles
- Five stocks we like better than BridgeBio Pharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
